ASCO: Exemestane Beats Tamoxifen in Early Breast Cancer
Monday, June 2, 2014 (Last Updated: 06/03/2014)
MONDAY, June 2, 2014 (HealthDay News) -- For premenopausal women with hormone receptor-positive early breast cancer, exemestane plus ovarian function suppression (OFS) is superior to tamoxifen plus OFS. This finding was presented at the annual meeting of the American Society of Clinical Oncology, held from May 30 to June 3 in Chicago.
Olivia Pagani, M.D., from the Institute of Oncology of Southern Switzerland in Bellinzona, and colleagues examined the results from two randomized phase 3 trials, TEXT and SOFT, which enrolled 4,690 premenopausal women with hormone receptor-positive early breast cancer. The women were randomized to receive five years of exemestane plus OFS or tamoxifen plus OFS.
The researchers found that the five-year disease-free survival was 91.1 percent in the exemestane plus OFS group, compared with 87.3 percent in the tamoxifen plus OFS group, with a significant reduction in the risk of disease-free survival in the exemestane group (hazard ratio [HR], 0.72; P = 0.0002). Similar reductions were seen for breast cancer-free interval (HR, 0.66; 95 percent confidence interval [CI], 0.55 to 0.80) and distant recurrence-free interval (HR, 0.78; 95 percent CI, 0.62-0.97), but there was no significant between-group difference noted in overall survival (HR, 1.14; 95 percent CI, 0.86 to 1.51).
"Our findings indicate that exemestane is better than tamoxifen, when given with ovarian function suppression, but longer follow up of these young women will be important to assess survival, and any long-term side effects and fertility," Pagani said in a statement.
The study was partially funded by Pfizer (manufacturer of exemestane) and Ipsen.
Hematology & Oncology
Copyright © 2014 HealthDay. All rights reserved.